|
Aug-07-26 01:13PM
|
Parkinson's drug developers are betting big on inflammation
|
link
|
(Proactive)
|
|
Aug-07-26 07:05AM
|
BioVie stock sinks on Phase IIb Parkinsons trial data
|
link
|
(Clinical Trials Arena)
|
|
Aug-06-26 09:03AM
|
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim
|
link
|
(Proactive)
|
|
Aug-06-26 07:30AM
|
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease
|
link
|
(GlobeNewswire)
|
|
Aug-05-26 12:18PM
|
BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial
|
link
|
(Proactive)
|
|
Jun-05-26 03:31PM
|
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?
|
link
|
(PR Newswire)
|
|
May-29-26 04:30PM
|
BioVie: Long COVID trial fully enrolled ICYMI
|
link
|
(Proactive)
|
|
May-27-26 08:00AM
|
Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2
|
link
|
(GlobeNewswire)
|
|
May-26-26 01:34PM
|
BioVie completes enrollment in Long COVID trial as need for treatments grows
|
link
|
(Proactive)
|
|
May-26-26 09:12AM
|
BioVie completes enrollment in Phase 2 Long COVID trial
|
link
|
(Proactive)
|
|
May-26-26 08:00AM
|
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
|
link
|
(GlobeNewswire)
|
|
May-19-26 08:31AM
|
BioVie completes final patient visit in Parkinson's drug trial
|
link
|
(Proactive)
|
|
May-18-26 08:00AM
|
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease
|
link
|
(GlobeNewswire)
|
|
May-09-26 09:00AM
|
BioVie CEO shares insights into long COVID trial - ICYMI
|
link
|
(Proactive)
|
|
May-04-26 11:24AM
|
BioVie advances long COVID trial, top-line data expected by summer
|
link
|
(Proactive)
|
|
Apr-27-26 08:00AM
|
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
|
link
|
(GlobeNewswire)
|
|
Apr-14-26 08:00AM
|
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting
|
link
|
(GlobeNewswire)
|
|
Apr-14-26 05:10AM
|
BioVie abstract on Parkinsons drug accepted for neurology conference
|
link
|
(Proactive)
|
|
Apr-14-26 03:52AM
|
Nasdaq jumps, Dow heads higher with Iran talks and earnings in focus
|
link
|
(Proactive)
|
|
Apr-11-26 07:27AM
|
BioVie CEO explains Bezisterim Parkinsons trial results - ICYMI
|
link
|
(Proactive)
|
|
Apr-09-26 01:44PM
|
BioVie targets neuroinflammation and insulin resistance in Parkinsons treatment approach
|
link
|
(Proactive)
|
|
Mar-26-26 11:00AM
|
BioVie targets Parkinsons at its source with lead drug bezisterim
|
link
|
(Proactive)
|
|
Mar-12-26 09:05AM
|
BioVie to present Parkinsons study data at AD/PD 2026 conference
|
link
|
(Proactive)
|
|
Mar-12-26 08:00AM
|
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
|
link
|
(GlobeNewswire)
|
|
Feb-23-26 08:00AM
|
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4
|
link
|
(GlobeNewswire)
|
|
Feb-12-26 03:50PM
|
Dow drops below 50,000 as S&P 500 falls back under years opening level
|
link
|
(Proactive)
|
|
Feb-12-26 08:33AM
|
BioVie highlights bezisterim research at ACP meeting
|
link
|
(Proactive)
|
|
Feb-12-26 08:00AM
|
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
|
link
|
(GlobeNewswire)
|
|
Feb-11-26 10:30AM
|
BioVie could offer first new Parkinsons therapy in decades
|
link
|
(Proactive)
|
|
Jan-08-26 08:00AM
|
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
|
link
|
(GlobeNewswire)
|
|
Dec-24-25 02:05PM
|
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
|
link
|
(PR Newswire)
|
|
Dec-11-25 12:00PM
|
What Makes BioVie (BIVI) a New Buy Stock
|
link
|
(Zacks)
|
|
Nov-19-25 08:00AM
|
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9
|
link
|
(GlobeNewswire)
|
|
Oct-24-25 08:20AM
|
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights
|
link
|
(Business Wire)
|
|
Sep-26-25 08:00AM
|
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
|
link
|
(GlobeNewswire)
|
|
Aug-13-25 04:05PM
|
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes
|
link
|
(GlobeNewswire)
|
|
Aug-11-25 04:05PM
|
BioVie Inc. Announces Closing of $12 Million Public Offering
|
link
|
(GlobeNewswire)
|
|
Aug-07-25 08:43PM
|
BioVie Inc. Announces Pricing of $12 Million Public Offering
|
link
|
(GlobeNewswire)
|
|
Jul-24-25 08:00AM
|
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
|
link
|
(GlobeNewswire)
|
|
Jul-22-25 08:00AM
|
BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors
|
link
|
(GlobeNewswire)
|
|
Jul-09-25 08:00AM
|
BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference
|
link
|
(GlobeNewswire)
|
|
Jun-26-25 08:00AM
|
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD)
|
link
|
(GlobeNewswire)
|
|
Jun-24-25 04:05PM
|
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders Congress
|
link
|
(GlobeNewswire)
|
|
May-15-25 08:00AM
|
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
|
link
|
(GlobeNewswire)
|
|
May-14-25 07:30AM
|
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
|
link
|
(GlobeNewswire)
|
|
May-07-25 08:00AM
|
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)
|
link
|
(GlobeNewswire)
|
|
May-05-25 08:00AM
|
BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
|
link
|
(GlobeNewswire)
|
|
Apr-16-25 08:00AM
|
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled
|
link
|
(GlobeNewswire)
|
|
Mar-27-25 08:00AM
|
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
|
link
|
(GlobeNewswire)
|
|
Mar-10-25 10:35AM
|
New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI)
|
link
|
(ACCESS Newswire)
|
|
Mar-03-25 08:40PM
|
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce
|
link
|
(ACCESS Newswire)
|
|
Feb-22-25 12:15PM
|
New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tanks Kevin Harrington and Sustainable Green Team (SGTM)
|
link
|
(ACCESS Newswire)
|
|
Jan-13-25 09:00AM
|
BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events
|
link
|
(ACCESS Newswire)
|
|
Nov-20-24 08:00AM
|
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
|
link
|
(GlobeNewswire)
|
|
Nov-04-24 08:00AM
|
BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded
|
link
|
(GlobeNewswire)
|
|
Oct-29-24 04:05PM
|
BioVie Inc. Announces Closing of Registered Direct Offering
|
link
|
(GlobeNewswire)
|
|
Oct-28-24 04:10PM
|
UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
link
|
(GlobeNewswire)
|
|
Oct-28-24 03:13PM
|
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
link
|
(GlobeNewswire)
|
|
Oct-24-24 04:10PM
|
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
|
link
|
(GlobeNewswire)
|
|
Oct-23-24 03:24PM
|
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
link
|
(GlobeNewswire)
|
|
Oct-23-24 09:19AM
|
BioVie Announces Stock Offering and Private Placement
|
link
|
(TipRanks)
|
|
Oct-23-24 08:00AM
|
Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024
|
link
|
(GlobeNewswire)
|
|
Oct-22-24 04:01PM
|
BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement
|
link
|
(GlobeNewswire)
|
|
Oct-21-24 03:08PM
|
BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
link
|
(GlobeNewswire)
|
|
Oct-15-24 08:00AM
|
BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin
|
link
|
(GlobeNewswire)
|
|
Oct-11-24 09:00AM
|
BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
link
|
(ACCESSWIRE)
|
|
Oct-01-24 08:00AM
|
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
|
link
|
(GlobeNewswire)
|
|
Sep-25-24 04:05PM
|
BioVie Inc. Announces Closing of Public Offering
|
link
|
(GlobeNewswire)
|
|
Sep-23-24 10:26PM
|
BioVie Inc. Announces Pricing of Public Offering
|
link
|
(GlobeNewswire)
|
|
Sep-23-24 04:05PM
|
BioVie Inc. Announces Proposed Public Offering
|
link
|
(GlobeNewswire)
|
|
Sep-16-24 08:00AM
|
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
|
link
|
(GlobeNewswire)
|
|
Sep-03-24 08:00AM
|
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
|
link
|
(GlobeNewswire)
|
|
Aug-27-24 08:45AM
|
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
|
link
|
(GlobeNewswire)
|
|
Aug-13-24 08:00AM
|
BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting
|
link
|
(GlobeNewswire)
|
|
Aug-12-24 07:30AM
|
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
|
link
|
(InvestorPlace)
|
|
Aug-08-24 06:00AM
|
BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease
|
link
|
(GlobeNewswire)
|
|
Aug-06-24 04:40PM
|
BioVie Inc. Announces Reverse Stock Split
|
link
|
(GlobeNewswire)
|
|
Jul-05-24 09:00AM
|
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
link
|
(ACCESSWIRE)
|
|
Jun-25-24 08:00AM
|
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024
|
link
|
(GlobeNewswire)
|
|
Jun-21-24 09:00AM
|
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
link
|
(ACCESSWIRE)
|
|
Jun-20-24 08:00AM
|
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress
|
link
|
(GlobeNewswire)
|
|
Jun-12-24 08:24AM
|
Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26
|
link
|
(GlobeNewswire)
|
|
Jun-04-24 08:00AM
|
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
|
link
|
(GlobeNewswire)
|
|
May-22-24 08:00AM
|
BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients
|
link
|
(GlobeNewswire)
|
|
May-15-24 10:53AM
|
BIVI Stock Earnings: BioVie Beats EPS for Q3 2024
|
link
|
(InvestorPlace)
|
|
Apr-29-24 11:43AM
|
BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID
|
link
|
(MT Newswires)
|
|
Apr-29-24 08:00AM
|
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
|
link
|
(GlobeNewswire)
|
|
Apr-25-24 08:00AM
|
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints
|
link
|
(GlobeNewswire)
|
|
Apr-18-24 08:00AM
|
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
|
link
|
(GlobeNewswire)
|
|
Apr-12-24 09:00AM
|
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
link
|
(ACCESSWIRE)
|
|
Mar-26-24 10:30AM
|
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation
|
link
|
(PR Newswire)
|
|
Mar-13-24 11:30AM
|
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie
|
link
|
(PR Newswire)
|
|
Mar-12-24 09:55AM
|
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
|
link
|
(Zacks)
|
|
Mar-12-24 09:41AM
|
BioVie Sued By Block & Leviton LLP for Securities Law Violations
|
link
|
(GlobeNewswire)
|
|
Mar-11-24 10:48AM
|
BioVie cuts 'most de-risked program,' will seek partners for phase-3 ready ascites program
|
link
|
(FierceBiotech.com)
|
|
Mar-11-24 08:00AM
|
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
|
link
|
(GlobeNewswire)
|
|
Mar-06-24 06:21PM
|
BIVI INVESTORS: Lead Plaintiff is Quickly Approaching; Contact Robbins LLP for Information About Your Rights
|
link
|
(GlobeNewswire)
|
|
Mar-06-24 05:00PM
|
BioVie Inc. Announces Closing of Public Offering
|
link
|
(GlobeNewswire)
|
|
Mar-05-24 11:39AM
|
Investors in BioVie Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights BIVI
|
link
|
(GlobeNewswire)
|
|
Mar-04-24 05:16PM
|
BioVie Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 19, 2024 deadline.
|
link
|
(GlobeNewswire)
|
ED-Finanzas